Merck Sterile Product Supply Issues Related To FDA Inspection Change – CEO
Executive Summary
FDA's changing approach to manufacturing inspections is one contributor to Merck's supply constraints for its injectable products, CEO Ray Gilmartin indicated at a Dec. 11 business update
You may also be interested in...
Pfizer Upgrading Terre Haute Plant In Response To FDA Warning Letter
Pfizer will complete an upgrade to its Terre Haute, Ind. manufacturing facility within six months, the company said after receiving a 1warning letter from FDA Jan. 30
Pfizer Upgrading Terre Haute Plant In Response To FDA Warning Letter
Pfizer will complete an upgrade to its Terre Haute, Ind. manufacturing facility within six months, the company said after receiving a 1warning letter from FDA Jan. 30
Merck Sterile Product Manufacturing Difficulties Affect Cancidas, Timoptic
Merck's recently launched antifungal Cancidas is in short supply as a result of manufacturing difficulties affecting the company's sterile product lines